acrivon therapeutics is a biotech company specializing in drug development through early clinical treatment success using our unique predictive biomarker approach. our technology platform is based on integrating drug-regulated, global proteomics with focused intact tissue digital imaging to develop drug-tailored biomarker signatures for prospective patient responder identification. the foundational science is based on proven, pathway-based methods linking active disease-driving mechanisms with the drug mechanism-of-action, to precisely match the therapy with patients who will benefit. our method is applicable across drug modalities
Company profile
Ticker
ACRV
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1.Acrivon AB • 2.Acrivon Securities Corporation ...
ACRV stock data
Latest filings (excl ownership)
8-K
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
14 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
EFFECT
Notice of effectiveness
30 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Results of Operations and Financial Condition
24 Apr 24
S-3
Shelf registration
17 Apr 24
8-K
Acrivon Therapeutics Announces $130 Million Private Placement Financing
9 Apr 24
S-8
Registration of securities for employees
29 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.02 mm | 25.02 mm | 25.02 mm | 25.02 mm | 25.02 mm | 25.02 mm |
Cash burn (monthly) | 3.80 mm | 237.75 k | 5.89 mm | 5.86 mm | 5.69 mm | 4.03 mm |
Cash used (since last report) | 6.04 mm | 377.54 k | 9.35 mm | 9.31 mm | 9.04 mm | 6.40 mm |
Cash remaining | 18.99 mm | 24.65 mm | 15.67 mm | 15.71 mm | 15.98 mm | 18.62 mm |
Runway (months of cash) | 5.0 | 103.7 | 2.7 | 2.7 | 2.8 | 4.6 |
Institutional ownership, Q4 2023
21.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 0 |
Closed positions | 42 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 153.51 mm |
Total shares | 6.75 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Chione | 3.86 mm | $60.63 mm |
Sands Capital Life Sciences Pulse Fund II | 1.65 mm | $27.50 mm |
Marshall Wace North America | 1.22 mm | $0.00 |
Exchange Traded Concepts | 13.29 k | $65.38 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 May 24 | Peter Blume-Jensen | Common Stock | Payment of exercise | Dispose F | No | No | 8.36 | 54,918 | 459.11 k | 2,561,894 |
14 May 24 | Eric Devroe | Common Stock | Payment of exercise | Dispose F | No | No | 8.36 | 613 | 5.12 k | 59,097 |
14 May 24 | Erick Gamelin | Common Stock | Payment of exercise | Dispose F | No | No | 8.36 | 402 | 3.36 k | 17,765 |
14 May 24 | Rasmus Holm-Jorgensen | Common Stock | Payment of exercise | Dispose F | No | No | 8.36 | 368 | 3.08 k | 27,258 |
14 May 24 | Kristina Masson | Common Stock | Payment of exercise | Dispose F | No | No | 8.36 | 490 | 4.10 k | 317,736 |
News
BMO Capital Reiterates Outperform on Acrivon Therapeutics, Maintains $25 Price Target
15 May 24
HC Wainwright & Co. Maintains Buy on Acrivon Therapeutics, Raises Price Target to $22
14 May 24
Acrivon Therapeutics Q1 EPS $(0.73) Beats $(0.84) Estimate
14 May 24
Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral
29 Apr 24
BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25
26 Apr 24
Press releases
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
24 Apr 24
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
16 Apr 24
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
10 Apr 24